NCT06147843Recruiting
French-German Cohort Study to Determine Factors Associated With Weight Loss in Amyotrophic Lateral Sclerosis
Source: ClinicalTrials.gov · Last updated 6 Aug 2026
Brief summary (registry, in English)
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. Studies have shown the importance of weight loss at the time of diagnosis and during the progression of the disease. However, the pathophysiological mechanisms behind weight loss remain unknown. Identifying these mechanisms could make it possible to propose an effective therapeutic strategy against weight loss for ALS patients, which could improve their survival and quality of life. In this context, the investigators are proposing an innovative multidisciplinary project aimed at structuring a large Franco-German cohort to identify the markers associated with weight loss in ALS. Participants will undergo high quality standard care for ALS patients. In addition, participants will be asked to respond different questionnaires and blood samples will be taken for analysis to identify biological markers.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 1000 (estimated)
- First submitted
- 12 Jul 2023
- Start date
- 17 Sept 2024
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- University Hospital, Limoges
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT06147843
What you commit to
- Study type: Interventional
- Planned participants: 1000
- From 17 Sept 2024 to the primary completion date, 30 Sept 2027
- 9 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who will not accept Riluzole therapy during their follow-up.
Other
- Inability to understand the requirements of the protocol.
- Cognitive inability to sign and comprehend the informed consent form.
Who the study is looking for
- Incident cases included at the time of diagnosis with a definite, probable, probable laboratory-supported, or possible ALS according to El Escorial revised criteria and Gold Coast criteria for early diagnosis.
- Incident ALS cases identified and followed-up in the participant ALS \& Other Motor Neuron Diseases Referral Centres: seven in France and two in Germany.
- Patients who signed the informed consent form.
- Adults aged \>18 years old
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (9)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Klinik für Medizinische Hochschule Hannover Carl-Neuberg-Str. 1 Coordinator of this site? Confirm its status | Hanover | Germany | Not yet recruiting |
| Klinik für Neurologie, Universitäts- und Rehabilitationskliniken Ulm (RKU Coordinator of this site? Confirm its status | Ulm | Germany | Not yet recruiting |
| CHU de Lille Coordinator of this site? Confirm its status | Lille | France | Recruiting |
| Limoges university hospital Coordinator of this site? Confirm its status | Limoges | France | Recruiting |
| Hopital de la Timone Coordinator of this site? Confirm its status | Marseille | France | Recruiting |
| Hôpital Gui Chauliac Coordinator of this site? Confirm its status | Montpellier | France | Recruiting |
| CHU de Nice Coordinator of this site? Confirm its status | Nice | France | Recruiting |
| Hôpital de la Pitié-Salpêtrière Coordinator of this site? Confirm its status | Paris | France | Recruiting |
| CHU de Tours Coordinator of this site? Confirm its status | Tours | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.